共查询到20条相似文献,搜索用时 841 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
目的探究经皮肝穿刺胆管引流术(PTBD)对Bismuth-Corlette I/II型肝门部胆管癌(HCCA)临床治疗效果及预后的影响。
方法回顾性分析2011年8月至2013年3月78例I/II型HCCA患者资料,其中42例患者采用PTBD治疗,设为PTBD组;36例患者采用经内镜鼻胆管引流术(ENBD)治疗,设为ENBD组。采用SPSS22.0软件进行分析,治疗前后肝功能指标等计量资料以(
±s)描述,独立t检验;引流成功率和并发症发生率采用χ2检验分析;5年生存率采用Kaplan-Meier法进行生存分析,进行Log-Rank检验。P<0.05差异有统计学意义。
结果PTBD组引流操作成功率85.7%(36/42)显著高于ENBD组63.9%(23/36), P<0.05;治疗后两组患者的TBA、TB、ALP和ALT水平均较治疗前有明显降低(P<0.05);PTBD组术后并发症率9.5%显著低于ENBD组27.8%(P=0.036);PTBD组5年生存率21.4%、平均生存时间(3.5±1.7)年;显著高于ENBD组5.6%(2.4±1.5)年,差异均有统计学意义(P<0.05)。
结论采用PTBD治疗I/II期型肝门胆管癌的临床疗效良好,可改善患者的肝功能,降低并发症发生率,提高患者5年生存率,值得临床推广应用。 相似文献
12.
目的 总结经皮介入技术治疗原位肝移植(OLT)术后胆管吻合口狭窄的经验.方法 回顾性分析2004年5月至2009年12月间25例OLT术后胆管吻合口狭窄患者的资料.其中22例行胆道外引流,3例第2次肝移植者行内外引流.25例的治疗方式包括单纯经皮经肝穿刺胆管引流术(PTBD)4例,PTBD配合球囊扩张术14例,PTBD配合胆道支架置入术7例(胆道内涵管5例,胆道金属支架2例).结果 PTBD手术成功率为100%,25例经介入治疗后15例(60%)治愈,10例(40%)好转,有效率达100%.7例首次行PTBD时引流管未能通过胆管狭窄段,其中3例于引流1周后再次调整引流管,成功通过狭窄段,余4例于引流术后4~8周时胆管狭窄段完全闭塞.引流期间发生胆道感染6例(24%),患者均未出现严重手术相关并发症.结论 经皮介入技术是治疗OLT术后胆管吻合口狭窄的一种安全、有效的方法.首次PTBD或PTBD后应短期内使引流管尽可能通过狭窄段,以免狭窄处永久闭塞.Abstract: Objective To describe the technique, efficacy, and safety of percutaneous interventional therapy for anastomotic biliary strictures after orthotopic liver transplantation (OLT).Methods From May 2004 to December 2009, 25 patients with anastomotic biliary strictures afte OLT were enrolled in our study. The modalities of biliary drainage included external drainage in 22patients, and external-internal drainage in 3 patients who underwent re-transplantation. All patients accepted percutaneous interventional therapy in our hospital, including single PTBD in 4 patients,PTBD combined with balloon dilation in 14 patients, balloon dilation and plastic stent implantation in 5 patients, balloon dilation and metallic stent implantation in 2 patients. The drainage catheters were exchanged every 1 to 3 months. Results The success rate of PTBD was 100%. Of the all 25patients, 15 (60 %) patients were cured, and 10 (40 %) patients were improved. The effective rate was 100 %. The drainage catheters failed to pass through the narrow bile duct when initial PTBD in 7 patients, and success was achieved in 3 patients by operation again after biliary drainage for one week.In the other 4 patients, anastomotic bile ducts were occluded, which was confirmed by cholangiography after biliary drainage for 4 to 8 weeks. The rate of biliary tract infection was 24 % (6/25). No serious procedure-related complications occurred in the all 25 patients. Conclusion PTBD combined with balloon dilation and biliary stenting is a effective and safe therapeutic modality for anastomotic biliary strictures after OLT, which can improve the patients' clinical symptoms and elevate patients' quality of life. To avoid bile duct occlusion, the drainage catheters should be passed through the narrow segments of bile duct when initial PTBD. 相似文献
13.
石力|汤礼军|汪涛|张炳印|李运明|陈涛|庞勇|田伏洲 《中国普通外科杂志》2012,21(8):918-921
目的:探讨经皮经肝胆道引流(PTBD)及经内镜逆行胰胆管造影(ERCP)置入胆道支架治疗肝门部胆管癌的临床应用价值。方法:对75例行金属胆道支架置入的肝门部胆管癌患者的临床资料进行回顾性分析。结果:PTBD组31例患者中29例实施支架放置,26例(89.7%)成功置入支架并发症发生率为6.5%,中位生存时间为26周;ERCP组44例患者中38例(86.4%)成功置入支架,并发症发生率为13.6%,中位生存时间为28周。29例单侧支架置入者和35例双侧支架置入者中位生存时间均为28周。结论:经PTBD及经ERCP的胆道支架置入对肝门部胆管癌均可获得良好的治疗效果。以PTBD方式放置时可采用单侧置入,以ERCP方式放置时应进行左右侧双支架置入。 相似文献
14.
Benign biliary stricture is a challenging problem in hepatobiliary surgery. Benign biliary stricture is associated with major portal vein variation, which is not be found in literatures. A male patient with benign biliary stricture was admitted to the Chinese PLA General Hospital in March, 2010.The stricture was located in the hilar confluence with intrahepatic biliary dilation and hepatolithiasis. The result of computed tomography showed that the hilar biliary confluence was compressed by the left portal vein and right anterior portal vein. The patient was cured after receiving gallbladder interposition, choledocholithotomy and T tube drainage. We suggested that the benign hilar biliary stricture due to portal vein variation may be named as biliary nut-craker syndrome. 相似文献
15.
目的比较可切除肝门部胆管癌术前经皮肝穿刺胆道引流(PTBD)及经逆行胰胆管造影(ERCP)内支架引流两种减黄方式的治疗效果,探讨最佳的术前引流方式。方法对2004年1月—2011年1月期间58例可切除的肝门部胆管癌术前行PTBD(35例)或ERCP(23例)减黄的患者的临床资料进行比较分析,比较两组的操作成功率、并发症发生率、胆道感染发生率以及引流效果。结果两组患者术前一般资料无统计学差异,PTBD组的操作成功率达100%,而ERCP组为87%(P=0.057);PTBD组2例出现胆道出血;而ERCP组出现1例十二指肠穿孔,2例十二指肠乳头出血,4例急性胰腺炎。ERCP组胆道感染的发生率高于PTBD组(43%vs.17%,P=0.028);两组均能于开腹手术前达到有效减黄,但ERCP组需时长于PTBD组(7周vs.4.5周,P=0.035),且更换引流物次数更多(2.5次vs.1.2次,P=0.029)。ERCP组8例(34.8%)需转为PTBD处理,其胆道感染的发生率为75.0%,平均需要进行4次更换引流物,术前平均引流时间为8周。PTBD组2例(5.7%)因胆汁引流量大(超过2000mL/d)转为ERCP... 相似文献
16.
[摘要] 目的 评价经胆囊管胆道引流(transcytic bile drainage,TBD)对肝移植术后胆道并发症的预防作用。方法 计算机检索PubMed、EMbase、sinoMed、Web of Science、the Cochrane Central Register of Controlled Trials(CENTRAL)、万方数据库、中国知网以及维普数据库等。查找并筛选出所有比较经胆囊管胆道引流(transcytic bile drainage,TBD)与T管引流(T-tube,T-T)或non-TBD对肝移植术后胆道并发症影响的随机对照试验(randomized controlled trial,RCT),同时手动检测纳入文献的参考文献,检索时间均为建库至2017年2月28日。主要结局指标:胆道并发症总的发生率、胆道狭窄、胆漏以及拔管相关性胆漏。按纳入、排除标准由2位评价者独立进行RCT的筛选、资料提取和质量评价后,采用RevMan(5.30版)
软件进行Meta分析,并采用GRADE pro3.6软件进行证据质量评价。结果 共纳入文献6篇,其中TBD与T管引流(T-T)对照研究3篇,TBD与胆管直接吻合(primary closure)对照研究文献1篇,TBD、T-T与直接吻合三者对照研究2篇。纳入病例542例,其中TBD组347例,T-T组102例,non-TBD组133例。Meta分析结果显示:与T-T组相比,TBD虽然不能降低胆道并发症总的发生率和总的胆漏发生率(7.3% vs 10.8%,RR=1.27,95% CI =0.50~1.16, P =0.21;23.9% vs 30.4%,RR=1.03,95% CI =0.30~1.45, P =0.30),但是能显著降低肝移植术后胆道狭窄和拔管后胆漏的发生率(14.3% vs 30.2%,RR=3.37,95% CI =0.33~0.75, P =0.0008;1.7% vs 18.8%,RR=2.48,95% CI =0.05~0.70, P =0.01)。与胆管直接吻合相比,TBD能降低肝移植术后胆道并发症总的发生率以及胆道狭窄的发生率,但差异没有统计学意义(25.8% vs 39.2%,RR=0.29,95% CI =0.58~1.50, P =0.77;14.0% vs 19.2%,RR=0.61,95%CI=0.54~3.24, P =0.54),并且不会明显增加胆漏的发生率(17.4% vs 15.8%,RR=0.47,95% CI =0.47~1.59, P =0.64)。结论 在肝移植术后胆道并发症的预防上,TBD与胆管直接吻合相当,优于T管引流。因此,TBD在肝移植胆管重建中是可行的,并且具有一定的临床价值。 相似文献
17.
恶性胆道梗阻是胰腺癌、壶腹癌和远端胆管癌常见的并发症,通常需行胆道引流以缓解症状.目前,经内镜逆行胰胆管造影术(ERCP)是恶性胆道梗阻病人胆道引流的标准方法.其他胆道引流方法包括旁路手术、经皮经肝胆管引流术(PTBD)和超声内镜引导下胆道引流术(EUS-BD).由于EUS-BD不破坏乳头结构且不需要通过狭窄的胆管放置... 相似文献
18.
肝门部胆管癌不同胆汁引流方式的疗效分析 总被引:3,自引:0,他引:3
目的回顾性分析不同经皮经肝胆汁引流方式对BismuthⅡ~Ⅳ型肝门部胆管癌患者术后疗效的影响。方法97例BismuthⅡ~Ⅳ型肝门部胆管癌患者按照不同引流方式分组:单侧和双侧引流组,每组又分为支架引流和引流管引流,比较各引流方式的术后疗效。结果单、双侧引流组的近期总胆红素下降程度分级差异无统计学意义(P〉0.05),中位生存期分别为7.5和6.7个月,生存率差异亦无统计学意义;单侧支架引流与引流管引流、单侧与双侧支架引流的中位生存期分别为6.0、6.5、6.0、4.3个月,组间生存率差异无统计学意义,但引流管组术后近远期并发症发生率高。结论对BismuthⅡ~Ⅳ型肝门部胆管癌患者可行单侧胆管引流以减轻黄疸,以胆管内支架治疗为首选,可获得满意临床疗效,且不影响近期胆红素下降和远期生存情况。 相似文献
19.
Preoperative management of hilar cholangiocarcinoma 总被引:5,自引:0,他引:5
M. Nagino Y. Nimura J. Kamiya S. Kondo M. Kanai M. Miyachi H. Yamamoto N. Hayakawa 《Journal of Hepato-Biliary-Pancreatic Surgery》1995,2(3):215-223
From both the therapeutic and diagnostic viewpoints, percutaneous transhepatic biliary drainage (PTBD) is crucial for the
preoperative management of hilar cholangiocarcinoma. The direct anterior approach under fluoroscopic guidance is the most
advantageous form of PTBD. Despite some advantages, endoscopic retrograde biliary drainage is contraindicated for preoperative
biliary decompression. Pertinent multiple catheterizations using PTBD result in an accurate diagnosis of cancer extent, and
produce effective relief of jaundice, as well as preventing the development of cholangitis. This, in turn, permits a rational
surgical strategy and improved postoperative recovery. Preoperative staging of hilar cholangiocarcinoma is achieved by tube
cholangiography through the PTBD catheter and by percutaneous transhepatic cholangioscopy. Angiography and percutaneous transhepatic
portography are also recommended to diagneous extramural invasion of cancer. Prevention of posthepatectomy liver failure is
the greatest challenge in the treatment of this disease. A multifactorial approach that combines several elements may provide
sufficient data for determing the safe limits of surgery and for predicting posthepatectomy liver failure. Preoperative percutaneous
transhepatic portal vein embolization (PTPE) is an effective method for preventing this intractable complication. 相似文献
20.
目的评价介入治疗对于肝细胞癌(HCC)并发梗阻性黄疸的疗效。方法对12例HCC伴发梗阻性黄疸接受介入治疗的患者,首先行PTBD,左侧人路3例,右侧2例,双侧人路7例。在PTC显示胆管形态恢复正常后,8例留置内支架(覆膜支架12枚,裸支架2枚).另4例单纯留置胆道引流管姑息治疗。结果PTBD成功率100%,4例并发胆管内出血。10例行胆管引流术1周后,血清总胆红素下降50%以上,肝功能好转.另2例在引流2周时血清总胆红素下降50%以上。生存时间自首次PTBD时间起3~13个月.平均生存时间6.2个月,6个月生存率41.67%,1年生存率16.67%。留置内支架的病例平均生存时间为6.52个月,仅行引流术而未植入内支架的病例平均生存时间为6.05个月,二者无显著统计学差异(P〉0.05)。7例患者接受经肝动脉化疗栓塞术治疗未发生并发症。结论有效的胆道引流是治疗HCC合并梗阻性黄疸的关键。胆管引流术和胆道内支架留置术都是有效的治疗方法,能够延长生存时间,创造进一步治疗机会。 相似文献